Downregulation of STOX1 is a novel prognostic biomarker for glioma patients

Storkhead box 1 (STOX1) is a winged helix transcription factor structurally and functionally related to the forkhead family of transcription factors. Recent studies have highlighted its role in the central nervous system and revealed hints in the development of glioma. However, the expression profil...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jin Fei-qin, Jin Lei, Wang Yan-ling
Formato:	article
Lenguaje:	EN
Publicado:	De Gruyter 2021
Materias:	bioinformatics glioma stox1 overall survival biomarker Biology (General) QH301-705.5
Acceso en línea:	https://doaj.org/article/9a58a2753be44cc399ae515e67951364
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9a58a2753be44cc399ae515e67951364
record_format	dspace
spelling	oai:doaj.org-article:9a58a2753be44cc399ae515e679513642021-12-05T14:10:42ZDownregulation of STOX1 is a novel prognostic biomarker for glioma patients2391-541210.1515/biol-2021-0119https://doaj.org/article/9a58a2753be44cc399ae515e679513642021-10-01T00:00:00Zhttps://doi.org/10.1515/biol-2021-0119https://doaj.org/toc/2391-5412Storkhead box 1 (STOX1) is a winged helix transcription factor structurally and functionally related to the forkhead family of transcription factors. Recent studies have highlighted its role in the central nervous system and revealed hints in the development of glioma. However, the expression profiles of STOX1, its association with clinicopathological characteristics, and potential functions in glioma remain unknown. In this study, we analyzed three publicly available datasets including CGGA, TCGA, and Rembrandt and revealed a grade-dependent reduction in STOX1 expression in glioma (P < 0.001). Chi-square test demonstrated that low STOX1 expression was significantly associated with older age at initial diagnosis (P < 0.001), less IDH1 mutation (P < 0.001), and advanced WHO grade (P < 0.001). Moreover, multivariate Cox regression analysis showed that STOX1 expression may serve as a novel independent prognostic biomarker in glioma patients. Bioinformatic functional analysis (GSEA) predicted that STOX1 was related to many key cancer pathways including P53 signaling pathway (P < 0.01), DNA replication (P < 0.05), homologous recombination (P < 0.05), and Wnt signaling pathway (P < 0.05). Taken together, these findings suggested that STOX1 may be used as a novel predictive molecular biomarker for glioma grading and overall patient survival. Further investigations on the functional roles and therapeutic value of STOX1 in glioma are warranted.Jin Fei-qinJin LeiWang Yan-lingDe Gruyterarticlebioinformaticsgliomastox1overall survivalbiomarkerBiology (General)QH301-705.5ENOpen Life Sciences, Vol 16, Iss 1, Pp 1164-1174 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	bioinformatics glioma stox1 overall survival biomarker Biology (General) QH301-705.5
spellingShingle	bioinformatics glioma stox1 overall survival biomarker Biology (General) QH301-705.5 Jin Fei-qin Jin Lei Wang Yan-ling Downregulation of STOX1 is a novel prognostic biomarker for glioma patients
description	Storkhead box 1 (STOX1) is a winged helix transcription factor structurally and functionally related to the forkhead family of transcription factors. Recent studies have highlighted its role in the central nervous system and revealed hints in the development of glioma. However, the expression profiles of STOX1, its association with clinicopathological characteristics, and potential functions in glioma remain unknown. In this study, we analyzed three publicly available datasets including CGGA, TCGA, and Rembrandt and revealed a grade-dependent reduction in STOX1 expression in glioma (P < 0.001). Chi-square test demonstrated that low STOX1 expression was significantly associated with older age at initial diagnosis (P < 0.001), less IDH1 mutation (P < 0.001), and advanced WHO grade (P < 0.001). Moreover, multivariate Cox regression analysis showed that STOX1 expression may serve as a novel independent prognostic biomarker in glioma patients. Bioinformatic functional analysis (GSEA) predicted that STOX1 was related to many key cancer pathways including P53 signaling pathway (P < 0.01), DNA replication (P < 0.05), homologous recombination (P < 0.05), and Wnt signaling pathway (P < 0.05). Taken together, these findings suggested that STOX1 may be used as a novel predictive molecular biomarker for glioma grading and overall patient survival. Further investigations on the functional roles and therapeutic value of STOX1 in glioma are warranted.
format	article
author	Jin Fei-qin Jin Lei Wang Yan-ling
author_facet	Jin Fei-qin Jin Lei Wang Yan-ling
author_sort	Jin Fei-qin
title	Downregulation of STOX1 is a novel prognostic biomarker for glioma patients
title_short	Downregulation of STOX1 is a novel prognostic biomarker for glioma patients
title_full	Downregulation of STOX1 is a novel prognostic biomarker for glioma patients
title_fullStr	Downregulation of STOX1 is a novel prognostic biomarker for glioma patients
title_full_unstemmed	Downregulation of STOX1 is a novel prognostic biomarker for glioma patients
title_sort	downregulation of stox1 is a novel prognostic biomarker for glioma patients
publisher	De Gruyter
publishDate	2021
url	https://doaj.org/article/9a58a2753be44cc399ae515e67951364
work_keys_str_mv	AT jinfeiqin downregulationofstox1isanovelprognosticbiomarkerforgliomapatients AT jinlei downregulationofstox1isanovelprognosticbiomarkerforgliomapatients AT wangyanling downregulationofstox1isanovelprognosticbiomarkerforgliomapatients
_version_	1718371798442049536

Downregulation of STOX1 is a novel prognostic biomarker for glioma patients

Ejemplares similares